Project
ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with one novel hormonal agent first line and non-progressive disease after second line treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial
Completed · 2017 until 2024
Fischer Stefanie, Harder Anja, Quinter Janine
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2017
End Date
2024
Financing
SAKK
Labels
prostate cancer